BONEFOS 800mg tablets medication leaflet

M05BA02 clodronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates

Clodronic acid is a bisphosphonate used to treat osteoporosis and hypercalcemia associated with bone metastases. It helps reduce bone loss by inhibiting osteoclast-mediated bone resorption.

It is commonly used in the treatment of cancer patients with bone metastases, helping to reduce pain and the risk of fractures. It can also be used to treat malignant hypercalcemia, a condition characterized by high calcium levels in the blood.

Clodronic acid is administered either orally or intravenously, depending on the medical indication. Side effects may include nausea, diarrhea, and, in rare cases, impaired kidney function. It is important for patients to strictly follow their doctor's recommendations to minimize risks.

Patients using clodronic acid should be periodically monitored to assess kidney function and blood calcium levels. It is contraindicated in cases of severe renal impairment.

General data about BONEFOS 800mg

Substance: clodronic acid

Date of last drug list: 01-03-2022

Commercial code: W57665001

Concentration: 800mg

Pharmaceutical form: tablets

Quantity: 60

Product type: original

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: BAYER OY - FINLANDA

Holder: BAYER OY - FINLANDA

Number: 8458/2015/01

Shelf life: 3 years

Pharmaceutical forms available for clodronic acid

Concentrations available for clodronic acid

300mg/5ml, 400mg, 60mg/ml, 800mg